ASH 2019 | FLAG-IDA and ponatinib in blast phase CML: MATCHPOINT trial

Mhairi Copland

Mhairi Copland, PhD, MBChB, FRCP, FRCPath, Paul O’Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, UK, discusses the results from the MATCHPOINT phase I/II trial. This study was designed to find a safe and effective dose of ponatinib when used in combination with FLAG-IDA chemotherapy (fludarabine, cytarabine, idarubicin and G-CSF) in patients with chronic myeloid leukemia (CML) whose disease has moved in to blast phase. Results confirm that FLAG-IDA plus ponatinib is a tolerable combination and represents a potentially important advance in the treatment of blast phase CML, a rare complication which currently has a very poor outcome. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter